嵌合抗原受体
免疫疗法
体内
输送系统
细胞疗法
离体
转染
抗原
医学
临床试验
癌症研究
免疫系统
细胞
免疫学
化学
细胞培养
生物
生物技术
生物医学工程
内科学
生物化学
遗传学
作者
Tingxuan Li,Ran Luo,Lina Su,Feng Lv,Lin Mei,Yongkang Yu
标识
DOI:10.1002/smtd.202300880
摘要
Abstract Chimeric antigen receptor (CAR) cell therapy is a great success and breakthrough in immunotherapy. However, there are still lots of barriers to its wide use in clinical, including long time consumption, high cost, and failure against solid tumors. For these challenges, researches are deplored to explore CAR cells to more appliable products in clinical. This minireview focuses on the advanced non‐viral materials for CAR‐T transfection ex vivo with better performance, delivery systems combined with other therapy for enhancement of CAR‐T therapy in solid tumors. In addition, the targeted delivery platform for CAR cells in vivo generation as a breakthrough technology as its low cost and convenience. In the end, the prospective direction and future of CAR cell therapy are discussed.
科研通智能强力驱动
Strongly Powered by AbleSci AI